<SEC-DOCUMENT>0001157523-16-004562.txt : 20160211
<SEC-HEADER>0001157523-16-004562.hdr.sgml : 20160211
<ACCEPTANCE-DATETIME>20160211135457
ACCESSION NUMBER:		0001157523-16-004562
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20160211
FILED AS OF DATE:		20160211
DATE AS OF CHANGE:		20160211

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aurinia Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001600620
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36421
		FILM NUMBER:		161410558

	BUSINESS ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
		BUSINESS PHONE:		250-708-4272

	MAIL ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a51278449.htm
<DESCRIPTION>AURINIA PHARMACEUTICALS INC. 6-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2016 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 10pt">
    <p style="text-align: center">
      <br>
      <font style="font-size: 16pt; font-family: Times New Roman"><b>UNITED
      STATES</b></font><b><font style="font-size: 16pt; font-family: Times New Roman"><br style="font-family: Times New Roman; font-size: 16pt"></font><font style="font-size: 16pt; font-family: Times New Roman">SECURITIES
      AND EXCHANGE COMMISSION</font></b><br><font style="font-size: 10pt; font-family: Times New Roman"><b>Washington,
      D.C. 20549</b></font>
    </p>
    <hr style="color: #000000; text-align: center; width: 100%; height: 1.0 pt">


    <p style="text-align: center">
      <font style="font-size: 14pt; font-family: Times New Roman"><b>FORM 6-K</b></font>
    </p>
    <hr style="color: #000000; text-align: center; width: 100%; height: 1.0 pt">


    <p style="text-align: center">
      <font style="font-family: Times New Roman"><b>&#160;</b></font><b><font style="font-size: 12pt; font-family: Times New Roman">REPORT
      OF FOREIGN PRIVATE ISSUER</font></b><br><font style="font-size: 12pt; font-family: Times New Roman"><b>PURSUANT
      TO RULE 13A-16 OR 15D-16 UNDER THE</b></font><br><font style="font-size: 12pt; font-family: Times New Roman"><b>SECURITIES
      EXCHANGE ACT OF 1934</b></font><br><br><font style="font-size: 10pt; font-family: Times New Roman"><b>Dated</b></font><font style="font-size: 10pt; font-family: Times New Roman">
      </font><font style="font-size: 10pt; font-family: Times New Roman"><b>February
      11, 2016</b></font><br><br><font style="font-size: 10pt; font-family: Times New Roman"><b>Commission
      File Number</b></font><b> 001-36421</b>
    </p>
    <hr style="color: #000000; text-align: center; width: 100%; height: 1.0 pt">


    <p style="text-align: center">
      <font style="font-size: 24pt"><b>AURINIA PHARMACEUTICALS INC.</b></font><br><b>(Exact
      name of Registrant as specified in its charter)</b><br><br>
    </p>
    <hr style="color: #000000; text-align: center; width: 100%; height: 1.0 pt">


    <p style="text-align: center">
      <b>N/A</b><br><b>(Translation of Registrant&#8217;s Name)</b><br><br>
    </p>
    <p style="text-align: center">
      <b>#1203-4464 Markham Street</b><br><b>Victoria, British Columbia</b><br><b>V8Z7X8</b><br><b>(250)
      708-4272</b><br><b>(Address and telephone number of registrant&#8217;s
      principle executive offices)</b>
    </p>
    <p style="text-align: center">

    </p>
    <hr style="color: #000000; text-align: center; width: 100%; height: 1.0 pt">


    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark whether the registrant files or will file annual reports
      under cover of Form 20-F or Form 40-F:</font>
    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman">Form 20-F &#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font><font style="font-size: 10pt; font-family: Times New Roman">
      &#160;&#160;&#160;&#160;Form 40-F&#160; </font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8864;</font>
    </p>
    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark if the registrant is submitting the Form 6-K in paper as
      permitted by Regulation S-T Rule 101(b)(1):&#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font><br>
    </p>
    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark if the registrant is submitting the Form 6-K in paper as
      permitted by Regulation S-T Rule 101(b)(7):&#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font><br>
    </p>
    <p style="text-indent: 30.0px; text-align: justify">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark whether by furnishing the information contained in this Form,
      the registrant is also thereby furnishing the information to the
      Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act
      of 1934.</font>
    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman">Yes &#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font><font style="font-size: 12pt">&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: Times New Roman">
      No &#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8864;</font>
    </p>
    <p style="text-indent: 30.0px; text-align: justify">
      <font style="font-size: 10pt; font-family: Times New Roman">If &quot;Yes&quot; is
      marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): Not a</font>pplicable.<br>
    </p>
    <div style="margin-right: 0pt; margin-bottom: 10pt; text-indent: 0pt; width: 100%; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman"><br style="font-size: 10pt; font-family: Times New Roman">
      </font><font style="font-size: 10pt; font-family: Times New Roman"><b>SIGNATURES</b></font>
    </p>
    <p style="text-indent: 30.0px">
      <font style="font-size: 10pt; font-family: Times New Roman">Pursuant to
      the requirements of the Securities Exchange Act of 1934, the registrant
      has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized. </font>
    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-size: 10pt; font-family: Times New Roman; width: 100%" cellspacing="0">
      <tr>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 6%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Dated:
          </p>
        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 44%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            February 11, 2016
          </p>
        </td>
        <td colspan="3">

        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: left" colspan="3">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Aurinia Pharmaceuticals Inc.</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: center" colspan="3">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="padding-left: 0.0px; padding-bottom: 2.0px; text-align: left; width: 6%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="padding-left: 0.0px; padding-bottom: 2.0px; text-align: left; width: 44%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="padding-left: 0.0px; padding-bottom: 2.0px; text-align: left; width: 3%">
          By:
        </td>
        <td valign="top" style="border-bottom-width: 1.0pt; border-bottom-color: black; padding-left: 0.0px; border-bottom-style: solid; text-align: left" colspan="2">
          <p style="margin-bottom: 0px; margin-top: 0px">
            /s/ Michael R. Martin
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 3%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 5%">
          Name:
        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 42%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Michael R. Martin
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 6%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 44%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 3%">

        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 5%">
          Title:
        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 42%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Chief Operating Officer
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">

    </p>
    <div style="margin-right: 0pt; margin-bottom: 10pt; text-indent: 0pt; width: 100%; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="font-size: 10pt; font-family: Times New Roman; text-align: center">
          2
        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <b>EXHIBIT&#160;INDEX</b>
    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-size: 10pt; font-family: Times New Roman; width: 100%" cellspacing="0">
      <tr>
        <td valign="bottom" style="border-bottom-width: 1.0pt; border-bottom-color: black; padding-left: 0.0px; border-bottom-style: solid; text-align: left; width: 7%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Exhibit</b>
          </p>
        </td>
        <td valign="bottom" style="padding-left: 0.0px; padding-bottom: 2.0px; text-align: left; width: 5%">
          &#160;
        </td>
        <td valign="bottom" style="border-bottom-width: 1.0pt; border-bottom-color: black; padding-left: 0.0px; border-bottom-style: solid; text-align: left; width: 88%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Description of Exhibit</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 7%">

        </td>
        <td style="width: 5%">

        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 88%">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="white-space: nowrap; padding-left: 0.0px; padding-right: 0.0px; text-align: left; width: 7%">
          99.1
        </td>
        <td style="width: 5%">

        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 88%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            News Release &#8211; Aurinia to Host Conference Call &amp; Webcast to Review
            Results from the AURION Study
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      3
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a51278449ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2016 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 8pt">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>Aurinia
      to Host Conference Call &amp; Webcast to Review Results from the AURION Study</b></font>
    </p>
    <p style="text-align: center">
      <i><font style="font-size: 12pt; font-family: Times New Roman"><b>Conference
      Call and Webcast with Slides, Tuesday February 16th at 4.30pm Eastern
      Time</b></font></i>
    </p>
    <p>
      VICTORIA, British Columbia--(BUSINESS WIRE)--February 11, 2016--<b>Aurinia
      Pharmaceuticals Inc</b>. (NASDAQ:AUPH / TSX:AUP) (&#8220;Aurinia&#8221; or the
      &#8220;Company&#8221;) will host a conference call and live webcast to discuss
      detailed results from its open label, single arm exploratory AURION (<u><i><b>A</b></i></u>urinia
      early <u><i><b>U</b></i></u>rinary protein <u><i><b>R</b></i></u>educt<u><i><b>ion</b></i></u>
      Predicts Response) study on Tuesday, February 16 at 4:30pm Eastern
      Standard Time. Participating in the call will be Stephen Zaruby, CEO,
      Dr. Neil Solomons, Chief Medical Officer, and Michael Martin, Chief
      Operating Officer.
    </p>
    <p>
      <u><i><b>Tuesday, February 16, 2016 @ 4:30pm Eastern/1:30pm Pacific</b></i></u><br>Domestic:
      888-329-8862<br>International: 719-785-1753<br>Conference ID: 3145908<br>Webcast
      with slides: <u>http://public.viavid.com/index.php?id=118297</u>
    </p>
    <p>
      <i>Replays, through March 1, 2016</i><br>Domestic: 877-870-5176<br>International:
      858-384-5517<br>Conference ID: 3145908
    </p>
    <p>
      <i><b>About Aurinia</b></i>
    </p>
    <p>
      Aurinia is a clinical stage pharmaceutical company focused on the global
      nephrology market. The fully-enrolled 265 patient Phase 2b AURA-LV
      clinical trial is evaluating the efficacy of its lead drug, voclosporin,
      as a treatment for active LN. LN is an inflammation of the kidneys, that
      if inadequately treated can lead to end-stage renal disease, making LN a
      serious and potentially life-threatening condition.
    </p>
    <p>
      Voclosporin is a novel and potentially best-in-class calcineurin
      inhibitor (&#8220;CNI&#8221;) with extensive clinical data in over 2,000 patients in
      other indications. Voclosporin is made by a modification of a single
      amino acid of the cyclosporine molecule (a CNI approved for use in
      transplant patients since 1983). This modification results in a more
      predictable pharmacokinetic and pharmacodynamic relationship, an
      increase in potency vs. cyclosporine, an altered metabolic profile, and
      potential for flat dosing.
    </p>
    <p>
      <i><b>About AURION:</b></i>
    </p>
    <p>
      The AURION study or &#8220;Aurinia Early Urinary Protein Reduction Predicts
      Response Study&#8221; is an open label, exploratory study being conducted in
      multiple sites in Malaysia to assess the short term predictors of
      response using voclosporin (23.7mg) in combination with mycophenolate
      mofetil and oral corticosteroids in patients with active lupus
      nephritis. This study will examine biomarkers of disease activity at 8
      weeks and their ability to predict response at 24 and 48 weeks.
    </p>
    <p>
      <i>We seek Safe Harbor</i>.
    </p>
    <p>

    </p>
    <p>
      CONTACT:<br><u><b>For More Information:</b></u><br>Aurinia
      Pharmaceuticals Inc.<br>Mr. Michael Martin, 250-708-4272<br>Chief
      Operating Officer<br><u>mmartin@auriniapharma.com</u><br>or<br>Renmark
      Financial Communications Inc<b>.</b><br>Barry Mire, 416-644-2020<br><u>bmire@renmarkfinancial.com</u><br>or<br>Laura
      Welsh, 514-939-3989<br><u>lwelsh@renmarkfinancial.com</u>
    </p>
    <p>

    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
